Dr Reddy’s to Acquire UCB for RS 800 Crore
Dr Reddy’s Laboratories is entering into a definitive agreement to acquire a Belgium based pharmaceutical firm UCB in India for Rs 800 crore.
According to media reports, the acquired UCB portfolio shall accelerate Dr Reddy’s presence in the high growth areas of dermatology, respiratory and paediatrics with market leading brands such as Atarax, Nootropil, Zyrtec, Xyzal, Xyzal M etc.
UCB’s Chief Operating Officer Mark McDade said, ” Finding the right company for our established brands in India was crucial, and Dr Reddy’s knowledge of the local market combined with their ambitious plans and excellent reputation, convinced us they were the right choice to drive the business forward.”
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
